

“Scheda Persona”

Template da compilare

Utilizzabile per: Direttore, Dirigente (Medico, Biologo, ...), Responsabile di struttura, Ricercatore

documento illustrativo

1. Scheda vuota

I campi con * sono obbligatori

Rinominare il file con Persona-Nome e cognome persona

Oggetto	Da Compilare
Nome*	Mario Achille
Cognome*	CATANZARO
Titolo	Dott.
Descrizione (Breve bio descrittiva)*	Attività clinica del reparto di Urologia Chirurgica Oncologica comprendente tutti gli ambiti ambulatoriale e sala operatoria (Endoscopia Urologica – Chirurgia Maggiore Urologica). In particolare ho sviluppato la tecnica mininvasiva (laparoscopica e robotica) e la gestione della chirurgia pelvica complessa in team con le altre unità operative del colon retto, sarcomi e ginecologi. Sono stato individuato come Tutor dalla Università degli Studi di Milano e Padova per gli Urologi in Formazione - Specializzandi in servizio presso la divisione OCU dell'Istituto Nazionale dei Tumori. Dal 2020 sono Responsabile della Prostate Cancer Unit per la parte clinica e chirurgica, con la gestione di oltre 1000 pazienti del Protocollo PRIAS di sorveglianza attiva nel carcinoma della Prostata. Sono parte del Team Multidisciplinare delle Neoplasie Genito-Urinarie. Ho mantenuto una attività scientifica con particolare attenzione alla gestione del data base prospettico della patologia rara carcinoma del pene (maggior casistica Italiana) e carcinoma del testicolo.
Strutture in cui opera e ruolo in struttura*	- DIRIGENTE MEDICO I LIVELLO - CHIRURGIA ONCOLOGICA UROLOGICA - RESPONSABILE PROSTATE CANCER UNIT
Specializzazione/i*	UROLOGIA

(obbligatorio solo per i dipartimenti di area clinica)	
Elenco pubblicazioni	BIBLIOGRAFIA MARIO ACHILLE CATANZARO [1] Nicolai N, Sangalli LM, Necchi A, Giannatempo P, Paganoni AM, Colecchia M, et al. A Combination of Cisplatin and 5-Fluorouracil With a Taxane in Patients Who Underwent Lymph Node Dissection for Nodal Metastases From Squamous Cell Carcinoma of the Penis: Treatment Outcome and Survival Analyses in Neoadjuvant and Adjuvant Settings. <i>Clinical Genitourinary Cancer</i> 2016;14:323–30. https://doi.org/10.1016/j.clgc.2015.07.009. [2] Necchi A, Giannatempo P, Lo Vullo S, Farè E, Raggi D, Marongiu M, et al. A prognostic model including pre- and postsurgical variables to enhance risk stratification of primary mediastinal nonseminomatous germ cell tumors: The 27-year experience of a referral center. <i>Clinical Genitourinary Cancer</i> 2015;13:87-93.e1. https://doi.org/10.1016/j.clgc.2014.06.014. [3] Bancroft EK, Page EC, Brook MN, Thomas S, Taylor N, Pope J, et al. A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. <i>The Lancet Oncology</i> 2021;22:1618–31. https://doi.org/10.1016/S1470-2045(21)00522-2. [4] Bandini M, Spiess PE, Pederzoli F, Marandino L, Brouwer OR, Albersen M, et al. A risk calculator predicting recurrence in lymph node metastatic penile cancer. <i>BJU International</i> 2020;126:577–85. https://doi.org/10.1111/bju.15177. [5] Sharma P, Djajadiningrat R, Zargar-Shoshtari K, Catanzaro M, Zhu Y, Nicolai N, et al. Adjuvant chemotherapy is associated with improved overall survival in pelvic node-positive penile cancer after lymph node dissection: A multi-institutional study. <i>Urologic Oncology: Seminars and Original Investigations</i> 2015;33:496.e17-496.e23. https://doi.org/10.1016/j.urolonc.2015.05.008. [6] Tang DH, Djajadiningrat R, Diorio G, Chipollini J, Ma Z, Schaible BJ, et al. Adjuvant pelvic radiation is associated with improved survival and decreased disease recurrence in pelvic node-positive penile cancer after lymph node dissection: A multi-institutional study. <i>Urologic Oncology: Seminars and Original Investigations</i> 2017;35:605.e17-605.e23. https://doi.org/10.1016/j.urolonc.2017.06.001. [7] Bandini M, Ross JS, Zhu Y, Ye D-W, Ornellas AA, Watkin N, et al. Association Between Human Papillomavirus Infection and Outcome of Perioperative Nodal Radiotherapy for Penile Carcinoma. <i>European Urology Oncology</i> 2021;4:802–10. https://doi.org/10.1016/j.euo.2020.10.011. [8] Necchi A, Lo Vullo S, Giannatempo P, Raggi D, Perrone F, Nicolai N, et al. Association of Androgen Receptor Expression on Tumor Cells and PD-L1 Expression in Muscle-Invasive and Metastatic Urothelial

- Carcinoma: Insights for Clinical Research. Clinical Genitourinary Cancer 2018;16:e403–10. <https://doi.org/10.1016/j.clgc.2017.09.016>.
- [9] Nazzani S, Catanzaro M, Biasoni D, Maccauro M, Stagni S, Torelli T, et al. Bilateral inguinal lymph-node dissection vs. unilateral inguinal lymph-node dissection and dynamic sentinel node biopsy in clinical N1 squamous cell carcinoma of the penis. Urologic Oncology: Seminars and Original Investigations 2023;41:210.e1-210.e8. <https://doi.org/10.1016/j.urolonc.2023.02.001>.
- [10] Testa I, Verzoni E, Catanzaro M, Biasoni D, Procopio G. Castration resistant prostate cancer: The activity of non chemotherapeutic agents. Adenocarcinoma: Pathogenesis, Treatment And Prognosis, 2012, p. 157–74.
- [11] Nicolai N, Necchi A, Raggi D, Biasoni D, Catanzaro M, Piva L, et al. Clinical outcome in testicular sex cord stromal tumors: Testis sparing vs radical orchiectomy and management of advanced disease. Urology 2015;85:402–6. <https://doi.org/10.1016/j.urology.2014.10.021>.
- [12] Nazzani S, Catanzaro M, Biasoni D, Maccauro M, Zaborra C, Stagni S, et al. Clinical Outcomes in Clinical N0 Squamous Cell Carcinoma of the Penis According to Nodal Management: Early, Delayed or Selective (following Dynamic Sentinel Node Biopsy) Inguinal Lymph-Node Dissection. Journal of Urology 2021;206:354–62. <https://doi.org/10.1097/JU.0000000000001775>.
- [13] Necchi A, Farè E, Vullo SL, Giannatempo P, Raggi D, Nicolai N, et al. Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective from a Referral Center. Clinical Genitourinary Cancer 2015;13:385-391.e1. <https://doi.org/10.1016/j.clgc.2015.02.002>.
- [14] Necchi A, Pond GR, Raggi D, Ottenhof SR, Djajadiningrat RS, Horenblas S, et al. Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis. Clinical Genitourinary Cancer 2017;15:548-555.e3. <https://doi.org/10.1016/j.clgc.2017.02.002>.
- [15] Necchi A, Nicolai N, Mariani L, Lo Vullo S, Giannatempo P, Raggi D, et al. Combination of paclitaxel, cisplatin, and gemcitabine (TPG) for multiple relapses or platinum-resistant germ cell tumors: Long-term outcomes. Clinical Genitourinary Cancer 2014;12:63-69.e1. <https://doi.org/10.1016/j.clgc.2013.07.005>.
- [16] Huelster HL, Chang A, Rose KM, Bandini M, Albersen M, Roussel E, et al. Concomitant vs Staged Therapeutic Inguinal Lymphadenectomy in Clinically Node Positive Penile Squamous Cell Carcinoma: Does It Make a Difference? Journal of Urology 2023;209:557–64. <https://doi.org/10.1097/JU.0000000000003099>.
- [17] Nicolai N, Colecchia M, Biasoni D, Catanzaro M, Stagni S, Torelli T, et al. Concordance and prediction ability of original and reviewed vascular invasion and other prognostic parameters of clinical stage i nonseminomatous germ cell testicular tumors after retroperitoneal lymph node dissection. Journal of Urology 2011;186:1298–302. <https://doi.org/10.1016/j.juro.2011.05.070>.
- [18] Spreafico C, Nicolai N, Lanocita R, Morosi C, Catanzaro M, Civelli E, et al. CT-guided percutaneous cryoablation of renal masses in selected

- Patients Crioablazione percutanea. *Radiologia Medica* 2012;117:593–605. <https://doi.org/10.1007/s11547-011-0742-1>.
- [19] Catanzaro M, Cappellano F, Giollo A, Ciotti GM, Pizzoccaro M, Santambrogio S, et al. Does percutaneous tibial nerve stimulation need a periodical maintenance session? Our 6-year experience. *vol. 15*, 2005, p. 184–5.
- [20] Marengi C, Alvisi MF, Palorini F, Avuzzi B, Badenchini F, Bedini N, et al. Eleven-year management of prostate cancer patients on active surveillance: What have we learned? *Tumori* 2017;103:464–74. <https://doi.org/10.5301/tj.5000649>.
- [21] Zargar-Shoshtari K, Djajadiningrat R, Sharma P, Catanzaro M, Zhu Y, Nicolai N, et al. Establishing criteria for bilateral pelvic lymph node dissection in the management of penile cancer: Lessons learned from an international multicenter collaboration. *Journal of Urology* 2015;194:696–702. <https://doi.org/10.1016/j.juro.2015.03.090>.
- [22] Raggi D, Giannatempo P, Miceli R, Farè E, Piva L, Biasoni D, et al. Etoposide, methotrexate, and dactinomycin alternating with cyclophosphamide and vincristine (EMACO) for male patients with HCG-expressing, chemoresistant germ cell tumors. *American Journal of Clinical Oncology: Cancer Clinical Trials* 2017;40:60–5. <https://doi.org/10.1097/COC.000000000000113>.
- [23] Zargar-Shoshtari K, Sharma P, Djajadiningrat R, Catanzaro M, Ye D-W, Zhu Y, et al. Extent of pelvic lymph node dissection in penile cancer may impact survival. *World Journal of Urology* 2016;34:353–9. <https://doi.org/10.1007/s00345-015-1593-5>.
- [24] Necchi A, Lo Vullo S, Perrone F, Raggi D, Giannatempo P, Calareso G, et al. First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study. *BJU International* 2018;121:348–56. <https://doi.org/10.1111/bju.14013>.
- [25] Monfardini S, Morlino S, Valdagni R, Catanzaro M, Tafa A, Bortolato B, et al. Follow-up of elderly patients with urogenital cancers: Evaluation of geriatric care needs and related actions. *Journal of Geriatric Oncology* 2017;8:289–95. <https://doi.org/10.1016/j.jgo.2017.02.011>.
- [26] Catanzaro M, Piva L, Torelli T, Biasoni D, Stagni S, Milani A, et al. Function sparing surgery in uro-oncology: germ cell tumors of the testis. *Urologia* 2012;79:15–9. <https://doi.org/10.5301/RU.2012.9736>.
- [27] Necchi A, Mariani L, Di Nicola M, Lo Vullo S, Nicolai N, Giannatempo P, et al. High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: Mature results of an Italian randomized phase II study. *Annals of Oncology* 2015;26:167–72. <https://doi.org/10.1093/annonc/mdu485>.
- [28] Chipollini J, Azizi M, Lo Vullo S, Mariani L, Zhu Y, Ye DW, et al. Identifying an optimal lymph node yield for penile squamous cell carcinoma: prognostic impact of surgical dissection. *BJU International* 2020;125:82–8. <https://doi.org/10.1111/bju.14883>.

- [29] Necchi A, Giannatempo P, Paolini B, Lo Vullo S, Marongiu M, Farè E, et al. Immunohistochemistry to enhance prognostic allocation and guide decision-making of patients with advanced urothelial cancer receiving first-line chemotherapy. *Clinical Genitourinary Cancer* 2015;13:171-177.e1. <https://doi.org/10.1016/j.clgc.2014.08.002>.
- [30] Giannatempo P, Alessi A, Miceli R, Raggi D, Farè E, Nicolai N, et al. Interim fluorine-18 fluorodeoxyglucose positron emission tomography forearly metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinoma. *Clinical Genitourinary Cancer* 2014;12:433-9. <https://doi.org/10.1016/j.clgc.2014.03.007>.
- [31] Catanzaro M, Cappellano F, Giollo A, Ciotti GM, Pizzoccaro M, Santambrogio S, et al. Is hyperpathic urethra the main target of percutaneous tibialis nerve neuromodulation (PTNM)? Our 6 years experience. vol. 19, 2005, p. 246-7.
- [32] Catanzaro M, Cappellano F, Giollo A, Ciotti GM, Pizzoccaro M, Santambrogio S, et al. Is hyperpathic urethra the most appropriate target of percutaneous tibialis nerve neuromodulation (PTNM)? Our 6-year experience. vol. 15, 2005, p. 173-4.
- [33] Alvisi MF, Repetto C, Rancati T, Badenchini F, Magnani T, Marengi C, et al. Italian cultural adaptation of the Memorial Anxiety for Prostate Cancer scale for the population of men on active surveillance. *Tumori* 2018;104:172-8. <https://doi.org/10.5301/tj.5000646>.
- [34] Nicolai N, Cattaneo F, Biasoni D, Catanzaro M, Torelli T, Zazzara M, et al. Laparoscopic Postchemotherapy Retroperitoneal Lymph-Node Dissection Can Be a Standard Option in Defined Nonseminomatous Germ Cell Tumor Patients. *Journal of Endourology* 2016;30:1112-9. <https://doi.org/10.1089/end.2016.0458>.
- [35] Nicolai N, Tarabelloni N, Gasperoni F, Catanzaro M, Stagni S, Torelli T, et al. Laparoscopic Retroperitoneal Lymph Node Dissection for Clinical Stage I Nonseminomatous Germ Cell Tumors of the Testis: Safety and Efficacy Analyses at a High Volume Center. *Journal of Urology* 2018;199:741-7. <https://doi.org/10.1016/j.juro.2017.09.088>.
- [36] Nazzani S, Stagni S, Biasoni D, Catanzaro M, Macchi A, Tesone A, et al. Laparoscopic retroperitoneal lymph-node dissection in metastatic nonseminomatous germ-cell tumors. *European Journal of Surgical Oncology* 2023;49:257-62. <https://doi.org/10.1016/j.ejso.2022.08.014>.
- [37] Necchi A, Mariani L, Giannatempo P, Raggi D, Farè E, Nicolai N, et al. Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer. vol. 12, 2014, p. 203-209.e1. <https://doi.org/10.1016/j.clgc.2013.11.022>.
- [38] Pizzoccaro M, Cappellano F, Torelli F, Catanzaro M, Catanzaro F. Management of recurrent stricture of appendicostomy in continent neobladder (Indiana pouch) with Memotherm® ureteral stent: Case report. vol. 11, 1997, p. 489-90. <https://doi.org/10.1089/end.1997.11.489>.
- [39] Necchi A, Nicolai N, Mariani L, Raggi D, Farè E, Giannatempo P, et al. Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ cell tumors: Long-term efficacy and safety outcomes. *Annals*

- of Oncology 2013;24:2887–92. <https://doi.org/10.1093/annonc/mdt271>.
- [40] Macchi A, Bruniera M, Nazzani S, Ceccato T, Colbacchini C, Taverna A, et al. mRNA-Based Urine Test Performance in High and Very-High Risk Non–Muscle-Invasive Bladder Cancer Patients Undergoing Contextual Endoscopic Follow-up (VERNAL: Vesical Tumor Early Monitoring: mRNA-Based Follow-up). *Clinical Genitourinary Cancer* 2025;23. <https://doi.org/10.1016/j.clgc.2025.102333>.
- [41] Catanzaro M, Cappellano F, Giollo A, Ciotti GM, Pizzoccaro M, Santambrogio S, et al. Needs percutaneous tibial nerve stimulation (PTNM) a periodical maintenance session? Our 6 years experience. vol. 19, 2005, p. 286–7.
- [42] Necchi A, Lo Vullo S, Raggi D, Perrone F, Giannatempo P, Calareso G, et al. Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: An open-label, single-arm, single-center, phase 2 study. *Urologic Oncology: Seminars and Original Investigations* 2018;36:8.e1-8.e8. <https://doi.org/10.1016/j.urolonc.2017.08.020>.
- [43] Necchi A, Lo Vullo S, Mariani L, Zhu Y, Ye D-W, Ornellas AA, et al. Nomogram-based prediction of overall survival after regional lymph node dissection and the role of perioperative chemotherapy in penile squamous cell carcinoma: A retrospective multicenter study. *Urologic Oncology: Seminars and Original Investigations* 2019;37:531.e7-531.e15. <https://doi.org/10.1016/j.urolonc.2019.04.003>.
- [44] Bandini M, Albersen M, Chipollini J, Pederzoli F, Zhu Y, Ye D-W, et al. Optimising the selection of candidates for neoadjuvant chemotherapy amongst patients with node-positive penile squamous cell carcinoma. *BJU International* 2020;125:867–75. <https://doi.org/10.1111/bju.15054>.
- [45] Nazzani S, Lorusso V, Catanzaro M, Torelli T, Silvani C, Macchi A, et al. Organ preservation and oncological efficacy of penoscopically controlled CO2 laser excision of penile squamous cell carcinoma: Early and late results in a high-volume center. *Urologic Oncology: Seminars and Original Investigations* 2025. <https://doi.org/10.1016/j.urolonc.2025.02.024>.
- [46] Chakiryan NH, Dahmen A, Bandini M, Pederzoli F, Marandino L, Albersen M, et al. Patterns of Recurrence following Inguinal Lymph Node Dissection for Penile Cancer: Optimizing Surveillance Strategies. *Journal of Urology* 2021;206:961–8. <https://doi.org/10.1097/JU.0000000000001790>.
- [47] Finazzi Agrò E, Cappellano F, Sciobica F, Catanzaro M, Asimakopoulos A, Giollo A, et al. Percutaneous tibial nerve stimulation (PTNS) in the treatment of LUTS secondary to Parkinson’s disease. vol. 16, 2006, p. 155–6.
- [48] Cappellano F, Finazzi Agrò E, Catanzaro M, Petta F, Giollo A, Sciobica F, et al. Percutaneous Tibial Nerve Stimulation (PTNS): Results at long term follow-up. vol. 20, 2006, p. 149–51.
- [49] Cappellano F, Finazzi Agrò E, Giollo A, Petta F, Catanzaro M, Miano R, et al. Percutaneous tibial nerve stimulation (PTNS): Results of long-term follow-up. vol. 16, 2006, p. 208–9.
- [50] Giannatempo P, Paolini B, Miceli R, Raggi D, Nicolai N, Faré E, et al.

- Persistent CD30 expression by embryonal carcinoma in the treatment time course: Prognostic significance of a worthwhile target for personalized treatment. *Journal of Urology* 2013;190:1919–24. <https://doi.org/10.1016/j.juro.2013.04.057>.
- [51] Necchi A, Giannatempo P, Lo Vullo S, Farè E, Raggi D, Nicolai N, et al. Postchemotherapy lymphadenectomy in patients with metastatic urothelial carcinoma: Long-term efficacy and implications for trial design. *Clinical Genitourinary Cancer* 2015;13:80–86.e1. <https://doi.org/10.1016/j.clgc.2014.06.003>.
- [52] Hugar LA, Peak TC, Naqvi M, Kim Y, Bandini M, Pederzoli F, et al. Predicting Limited Survival Following Inguinal Lymph Node Dissection in Penile Cancer: Should We Revisit the Goals of Care? *Urology* 2023;180:176–81. <https://doi.org/10.1016/j.urology.2023.07.006>.
- [53] Gandellini P, Ciniselli CM, Rancati T, Marengi C, Doldi V, El Bezawy R, et al. Prediction of grade reclassification of prostate cancer patients on active surveillance through the combination of a three-mirna signature and selected clinical variables. *Cancers* 2021;13. <https://doi.org/10.3390/cancers13102433>.
- [54] Johnstone PAS, Boulware D, Djajadiningrat R, Ottenhof S, Necchi A, Catanzaro M, et al. Primary Penile Cancer: The Role of Adjuvant Radiation Therapy in the Management of Extranodal Extension in Lymph Nodes. *European Urology Focus* 2019;5:737–41. <https://doi.org/10.1016/j.euf.2018.10.007>.
- [55] Necchi A, Lo Vullo S, Nicolai N, Raggi D, Giannatempo P, Colecchia M, et al. Prognostic Factors of Adjuvant Taxane, Cisplatin, and 5-Fluorouracil Chemotherapy for Patients With Penile Squamous Cell Carcinoma After Regional Lymphadenectomy. vol. 14, 2016, p. 518–23. <https://doi.org/10.1016/j.clgc.2016.03.005>.
- [56] Raggi D, Mariani L, Giannatempo P, Lo Vullo S, Giardiello D, Nicolai N, et al. Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation. *Urologic Oncology: Seminars and Original Investigations* 2015;33:332.e19–332.e24. <https://doi.org/10.1016/j.urolonc.2015.04.008>.
- [57] Necchi A, Nicolai N, Colecchia M, Catanzaro M, Torelli T, Piva L, et al. Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. *Journal of Clinical Oncology* 2011;29:e650–2. <https://doi.org/10.1200/JCO.2011.34.8367>.
- [58] Torelli T, Lughezzani G, Catanzaro M, Nicolai N, Colecchia M, Biasoni D, et al. Prostatic metastases from testicular nonseminomatous germ cell cancer: Two case reports and a review of the literature. *Tumori* 2013;99:e203–7. <https://doi.org/10.1177/030089161309900513>.
- [59] Torelli T, Lughezzani G, Catanzaro M, Nicolai N, Colecchia M, Biasoni D, et al. Prostatic metastases from testicular nonseminomatous germ cell cancer: Two case reports and a review of the literature. *Tumori* 2013;99:e203–7. <https://doi.org/10.1177/030089161309900513>.
- [60] Cappellano F, Maderna L, Fornara C, Salvatore S, Aquino A, Catanzaro

- M, et al. Pudendal nerve block under neurophysiologic guidance for the treatment of chronic pelvic pain (CPP): Technical notes and clinical results. vol. 18, 2008, p. 40–1.
- [61] Cappellano F, Fornara C, Mennea S, Ciotti MG, Catanzaro M, Pizzoccaro M, et al. Pudendal nerve brain mapping in healthy subjects: A proposal for a new neurophysiological tool for the functional evaluation of CNS. vol. 15, 2005, p. 181–3.
- [62] Cappellano F, Fornara C, Mennea S, Ciotti MG, Catanzaro M, Pizzoccaro M, et al. Pudendal nerve brain mapping in healthy subjects: Proposal of a new neurophysiological tool for the functional evaluation of CNS. vol. 19, 2005, p. 243–5.
- [63] Nicolai N, Bianchi E, Donati I, L'Acqua C, Brunelli C, Biasoni D, et al. Quality of life and pain control following laparoscopic retroperitoneal lymph node dissection in early-stage nonseminoma. *Tumori* 2015;101:650–6. <https://doi.org/10.5301/tj.5000354>.
- [64] Avuzzi B, Tittarelli A, Andreani S, Noris Chiorda B, Seregini E, Villa S, et al. Radiotherapy after testis-sparing surgery for seminoma in monorchid patients: safety and efficacy. *Tumori* 2022;108:165–71. <https://doi.org/10.1177/0300891621992428>.
- [65] Giannatempo P, Greco T, Mariani L, Nicolai N, Tana S, Farè E, et al. Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: A systematic review and meta-analysis of patient outcomes. *Annals of Oncology* 2015;26:657–68. <https://doi.org/10.1093/annonc/mdl447>.
- [66] Lughezzani G, Catanzaro M, Torelli T, Piva L, Biasoni D, Stagni S, et al. Relationship between lymph node ratio and cancer-specific survival in a contemporary series of patients with penile cancer and lymph node metastases. *BJU International* 2015;116:727–33. <https://doi.org/10.1111/bju.12510>.
- [67] Nazzani S, Zaborra C, Biasoni D, Catanzaro M, Macchi A, Stagni S, et al. Renal tumor biopsy in patients with cT1b-T4-M0 disease susceptible to radical nephrectomy: analysis of safety, accuracy and clinical impact on definitive management. *Scandinavian Journal of Urology* 2022;56:367–72. <https://doi.org/10.1080/21681805.2022.2092549>.
- [68] Nazzani S, Catanzaro M, Biasoni D, Maccauro M, Zaborra C, Stagni S, et al. Reply by Authors. *Journal of Urology* 2021;206:363. <https://doi.org/10.1097/JU.0000000000001775.03>.
- [69] Nicolai N, Miceli R, Necchi A, Biasoni D, Catanzaro M, Milani A, et al. Retroperitoneal lymph node dissection with no adjuvant chemotherapy in clinical stage i nonseminomatous germ cell tumours: Long-term outcome and analysis of risk factors of recurrence. *European Urology* 2010;58:912–8. <https://doi.org/10.1016/j.eururo.2010.08.032>.
- [70] Nicolai N, Nazzani S, Tesone A, Macchi A, Piva L, Salvioni R, et al. Retroperitoneal lymph-node dissection (RPLND) as upfront management in stage II germ-cell tumours: Evaluation of safety and efficacy. *Tumori* 2023;109:379–86. <https://doi.org/10.1177/03008916221112697>.
- [71] Nicolai N, Necchi A, Piva L, Stagni S, Catanzaro MA, Biasoni D, et al. [Retroperitoneal surgery in the treatment of germ-cell tumors of the testis: retroperitoneal lymph node dissection (RPLND)]. *Urologia*

- 2010;77:84–7. <https://doi.org/10.1177/039156031007700202>.
- [72] Chakiryan NH, Dahmen A, Bandini M, Pederzoli F, Marandino L, Albersen M, et al. Risk factors and survival outcomes for upstaging after inguinal lymph node dissection for cN1 penile squamous cell carcinoma. *Urologic Oncology: Seminars and Original Investigations* 2021;39:838.e7-838.e13. <https://doi.org/10.1016/j.urolonc.2021.08.028>.
- [73] Cappellano F, Ciotti MG, Pizzoccaro M, Catanzaro M, Santambrogio S, Catanzaro F. Sacral root neuromodulation in the treatment of female urge and mixed urinary incontinence. *Urogynaecologia International Journal* 1998;12:111–21.
- [74] Lorenzoni A, Nazzani S, Argiroffi G, Catanzaro M, Aliberti G, Nicolai N, et al. Sentinel node biopsy in male genitourinary cancers: state of the art and future developments. *Clinical and Translational Imaging* 2023;11:559–65. <https://doi.org/10.1007/s40336-023-00599-9>.
- [75] Thulasi Seetha S, Garanzini E, Tenconi C, Marengi C, Avuzzi B, Catanzaro M, et al. Stability of Multi-Parametric Prostate MRI Radiomic Features to Variations in Segmentation. *Journal of Personalized Medicine* 2023;13. <https://doi.org/10.3390/jpm13071172>.
- [76] Pizzoccaro M, Bernardini P, Cappellano F, Ciotti G, Catanzaro M, Catanzaro F. Stents in the treatment of stenosis of the entero-urethral junction in continent diversion: case reports. *Archivio Italiano Di Urologia, Andrologia : Organo Ufficiale [Di] Società Italiana Di Ecografia Urologica e Nefrologica / Associazione Ricerche in Urologia* 1996;68:319–22.
- [77] De Gobbi A, Biasoni D, Catanzaro M, Nicolai N, Piva L, Stagni S, et al. Surgery of locally advanced and metastatic kidney cancer after tyrosine kinase inhibitors therapy: Single institute experience. *Tumori* 2018;104:388–93. <https://doi.org/10.5301/tj.5000596>.
- [78] Nazzani S, Catanzaro M, Bruniera M, Torelli T, Macchi A, Stagni S, et al. Surveillance or Dynamic Sentinel Lymph-Node Biopsy in Low-Risk Clinically N0 Penile Squamous Cell Carcinoma: Single-Institution Real World Data. *Clinical Genitourinary Cancer* 2024;22:544–8. <https://doi.org/10.1016/j.clgc.2024.01.009>.
- [79] Nicolai N, Biasoni D, Catanzaro MA, Colecchia M, Trama A, Hackl M, et al. Testicular germ-cell tumours and penile squamous cell carcinoma: Appropriate management makes the difference. *European Journal of Surgical Oncology* 2019;45:60–6. <https://doi.org/10.1016/j.ejso.2018.02.006>.
- [80] Catanzaro F, Torelli F, Catanzaro M, Cappellano F, Pizzoccaro M, Baruffi M, et al. The conservative management of high risk bladder transitional cell carcinoma T1G3. vol. 68, 1996, p. 21–4.
- [81] Bancroft EK, Page EC, Brook MN, Pope J, Thomas S, Myhill K, et al. The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers. *BJU International* 2024;134:484–500. <https://doi.org/10.1111/bju.16432>.
- [82] Lughezzani G, Catanzaro M, Torelli T, Piva L, Biasoni D, Stagni S, et al. The relationship between characteristics of inguinal lymph nodes and pelvic lymph node involvement in penile squamous cell carcinoma: A single institution experience. *Journal of Urology* 2014;191:977–82.

	https://doi.org/10.1016/j.juro.2013.10.140. [83] Nicolai N, Catanzaro M, Zazzara M. The role of surgery in metastatic squamous cell carcinoma of the penis. <i>Current Opinion in Urology</i> 2016;26:596–601. https://doi.org/10.1097/MOU.0000000000000328. [84] Salvioni R, Nicolai N, Necchi A, Torelli T, Piva L, Stagni S, et al. [The treatment of early-stage germ cell tumors of the testis (GCTT)]. <i>Urologia</i> 2012;79:81–8. https://doi.org/10.5301/RU.2012.9047. [85] Pizzoccaro M, Catanzaro M, Stubinski R, Cappellano F, Ciotti G, Catanzaro F. The use of temporary stents in the treatment of urethral stenosis. <i>Archivio Italiano Di Urologia, Andrologia : Organo Ufficiale [Di] Società Italiana Di Ecografia Urologica e Nefrologica / Associazione Ricerche in Urologia</i> 2002;74:111–2. [86] Necchi A, Colecchia M, Nicolai N, Piva L, Catanzaro M, Biasoni D, et al. Towards the definition of the best management and prognostic factors of teratoma with malignant transformation: A single-institution case series and new proposal. <i>BJU International</i> 2011;107:1088–94. https://doi.org/10.1111/j.1464-410X.2010.09705.x. [87] Torelli T, Catanzaro MA, Nicolai N, Giannatempo P, Necchi A, Raggi D, et al. Treatment of Carcinoma In Situ of the Glans Penis With Topical Imiquimod Followed by Carbon Dioxide Laser Excision. <i>Clinical Genitourinary Cancer</i> 2017;15:e483–7. https://doi.org/10.1016/j.clgc.2017.01.009. [88] Torelli F, Pizzoccaro M, Cappellano F, Catanzaro M, Bernasconi F, Catanzaro F. Urethral implantation of gax collagen in stress urinary incontinence: Ultrasound study after short and long term follow-up. <i>Urogynaecologia International Journal</i> 1998;12:63–8. [89] Patelli E, Mantovani F, Catanzaro M, Pisani E. Urgency-frequency syndrome in women: interstitial cystitis and correlated syndromes. <i>Archivio Italiano Di Urologia, Andrologia : Organo Ufficiale [Di] Società Italiana Di Ecografia Urologica e Nefrologica / Associazione Ricerche in Urologia</i> 1999;71:317–20. [90] Patelli E, Catanzaro M, Mantovani F, Colombo F. Uro-andrologic prevention of male infertility. <i>Archivio Italiano Di Urologia, Andrologia : Organo Ufficiale [Di] Società Italiana Di Ecografia Urologica e Nefrologica / Associazione Ricerche in Urologia</i> 2001;73:209–14. [91] Catanzaro F, Pizzoccaro M, Cappellano F, Catanzaro M, Ciotti G, Giollo A. Vaginal repair of vesico-vaginal fistulas: Our experience. vol. 77, 2005, p. 224–5.
Elenco Progetti di Ricerca	OVD-ETAR
Contatti	• SEGRETERIA.UROLOGIA @ISTITUTOTUMORI.MI.IT • SEGRETERIA UROLOGIA 0223902707
CV	• <u>Dirigente Medico di I livello della disciplina di Urologia</u> con

incarico interinale a tempo pieno *dal 22-12-1997 al 21-08-1998*
presso l'azienda Ospedaliera "Ospedale Civile" di Vimercate -
Presidio di Desio.

- Urologia funzionale
- Calcolosi
- *Assistente* della Unità Operativa di Urologia - *Policlinico Multimedica IRCCS* - Sesto SG dal 01-01-2002 al 31-12-2005, rapporto regolato dal CCNL per il personale medico dipendente di case di cura private
- *Aiuto* della Unità Operativa di Urologia - *Policlinico Multimedica IRCCS* - Sesto SG dal 01-01-2006 al 01-01-2009, rapporto regolato dal CCNL per il personale medico dipendente di case di cura private
 - Urologia funzionale: Uroginecologia e Neuromodulazione
 - Calcolosi
 - Urologia oncologica
- *Dirigente Medico 1° livello* della Struttura Complessa di Chirurgia Urologica - *Fondazione IRCCS Istituto Nazionale dei Tumori di Milano* dal 02-01-2009
 - Urologia Oncologica
 - Responsabile del PDTA e del data base della patologia rara carcinoma spino cellulare del pene
 - Laparoscopia/Robotica nella chirurgia Maggiore: nefrectomia, resezione renale, linfadenectomie retro peritoneali, cistectomia, prostatectomia radicale.
 - Prostate cancer unit: core business in qualità di Urologo
 - Responsabile della gestione delle biopsie prostatiche con tecnica Fusion

	• Responsabile Prostate cancer Unit della Fondazione IRCCS Milano dal 20-luglio-2020 ad oggi
Fototessera	Avete la foto sul sito

2. Ruoli disponibili

- Direttore di dipartimento
- Direttore di struttura complessa
- Responsabile di struttura semplice
- Responsabile di struttura semplice dipartimentale
- Dirigente Farmacista
- Dirigente Biologo
- Dirigente Medico
- Dirigente Fisico
- Dirigente Psicologo
- Ricercatore Medico
- Ricercatore Group Leader (dirigenti ricercatori sanitari che gestiscono team e specifici progetti)

3. Specializzazioni

Per l'elenco delle specializzazioni si veda l'elenco allegato e la relativa tabella delle equipollenze